Teva agreed in July to purchase Allergan’s generics unit for USD 40.5 billion in cash and stock, establishing the Israeli company as the largest manufacturer of generic drugs at a time when pharmaceutical benefits managers and insurers are putting increased pressure on drug prices.
| Subscribe To Our Free Newsletter |
